Topline results from the Phase 3 REVEAL-1 trial demonstrate that subcutaneous elegrobart achieved rapid, clinically meaningful reductions in proptosis and diplopia in active Thyroid Eye Disease patients with convenient Q4W or Q8W dosing.
Brepocitinib, a novel oral TYK2/JAK1 inhibitor, demonstrated significant clinical efficacy in the phase 3 VALOR trial for dermatomyositis, achieving superior improvement scores, higher remission rates and meaningful reductions in corticosteroid use compared with placebo. Rapid improvements in itch, muscle strength and quality of life were observed, with a favorable safety profile and no increase in major adverse events such as thrombosis or malignancy. These findings mark a major advancement in targeted therapy for this difficult-to-treat autoimmune disease.
A pre-specified subgroup analysis of the VESALIUS-CV trial demonstrates that the PCSK9 inhibitor evolocumab significantly reduces major adverse cardiovascular events and all-cause mortality in high-risk patients with diabetes who do not have established atherosclerosis, supporting earlier and more intensive lipid-lowering therapy.
The phase 3 VALOR trial shows that brepocitinib significantly improves skin disease, muscle strength, and functional disability in adults with dermatomyositis. As the first modern targeted therapy to demonstrate positive results, brepocitinib may transform treatment options while reducing steroid reliance.
A 16-week Mediterranean diet program significantly improved psoriasis severity and quality of life, independent of weight loss.
Exercise, not liraglutide, reduced atherosclerosis after weight loss in adults with obesity, improving inflammation and heart health.
Olezarsen cuts triglycerides up to 60%, normalizing levels in 85% of high-risk patients.
Baxdrostat lowers BP in resistant hypertension, offering a new treatment option.
Metabolic syndrome raises Parkinsonโs risk by 39%, especially with genetic predisposition.
Oral testosterone undecanoate (Jatenzo) boosted T levels & sexual function in 92% of hypogonadal men by day 105 in phase 3 trial.
